Messing K, Bradley W E
Mutat Res. 1985 Oct;152(1):107-12. doi: 10.1016/0027-5107(85)90051-x.
Human in vivo mutant frequencies can be measured by cloning freshly isolated lymphocytes in selective media containing 6-thioguanine (TG). This method was applied to monitoring environmental mutagenesis, by studying lymphocytes separated from peripheral blood of 12 cancer patients undergoing radiotherapy. Before therapy, cancer patients had an average 8.6 X 10(-6) mutants/cell, compared to 2.4 X 10(-6) mutants/cell for heart patients and 1.1 X 10(-6) mutants/cell for healthy controls. After exposure of cancer patients to 50 Gy of gamma-radiation delivered to the treated area, or an estimated 4 Gy received by each lymphocyte, patients averaged 36.8 X 10(-6) mutants/viable cell.
人体内的突变频率可以通过在含有6-硫鸟嘌呤（TG）的选择性培养基中克隆新鲜分离的淋巴细胞来测量。通过研究从12名接受放疗的癌症患者外周血中分离出的淋巴细胞，该方法被应用于监测环境诱变。治疗前，癌症患者平均每细胞有8.6×10⁻⁶个突变体，相比之下，心脏病患者为2.4×10⁻⁶个突变体/细胞，健康对照为1.1×10⁻⁶个突变体/细胞。癌症患者在治疗区域接受50 Gy的γ射线照射后，或每个淋巴细胞估计接受4 Gy的辐射后，患者平均每存活细胞有36.8×10⁻⁶个突变体。
